1. The document appears to be a design document created by Liu Jane in 2010.12. 2. It includes sections on methodology, case studies, conclusions, and recommendations regarding cost-effectiveness analyses and calculating ICER thresholds. 3. The document compares approaches used by organizations like NICE and IQWiG and evaluates factors like quality of life improvements.

1. Designed by Liu Jane 2010.12

2. Start!
Designed by Liu Jane 2010.12

3. 2

4. 2
—

5. 3
+
+
+ NICE
and IQWiG

6. 4

7. 5
1 2

8. 6
+
+ Eisa’s Aricept
+ Eisa’s Aricept 518.7 (5mg), (1999.11)
+ 373 JPY
+ 65.37 JPY
+ 55.33 JPY
+ 24.7 JPY
+ 518.7 JPY
+

9. 7
+
3 2
$7/ $?/
($X)=($7*3 ) 2 $10.5
+

10. 8

11. 8
+
+ 70%-120%
+
+ 1 35%-65%
+ 2 5%-30%
+
+ 1 10 20
+ 2 5
+

12. 9
+ (70%-120%)
+
1
2

13. 10
+ 1 35%-65%
+ 3 2
+ 2 5%-30%
+
1
2
3
4

14. 11
2002 2002 2006 2008
40 40 100 50 100 70 120
1 10 15 30 25 40 35 60
2 3 5 10 5 20 5 30

15. 12

16. 12
(1997-2008)

17. 12
(1997-2008)
404

18. 12
(1997-2008)
404
CAM 72

19. 12
(1997-2008)
404
CAM 72
SECM 332

20. 12
(1997-2008)
404
CAM 72
SECM 332

21. 12
(1997-2008)
404
CAM 72
SECM 332
2(0.5%)

22. 12
(1997-2008)
404
CAM 72
SECM 332
2(0.5%)
1 10(2.5%)

23. 12
(1997-2008)
404
CAM 72
SECM 332
2(0.5%)
1 10(2.5%)
2 68(16.8 )

24. 13
+
+ ( )
+ ( )
+ ...
+

25. 14
+
+
+

26. 15
+
+
+ “
” 2010.4
+

27. 16
+
+
+

28. Jane Liu 2010
17

29. Jane Liu 2010
• 2
5.75%(2010)
•
10% 15%
10% 25%
• α
2.5% 5.3%
18

30. Jane Liu 2010
2010.4
15447
624
12
4
14807
15447
8
5
3
19

31. Jane Liu 2010
1. 15 ; 2.
2010
8.38%
20

32. Jane Liu 2010
( )
[ (8.38%-2%)]*0.8%=5.10%
( )
1.
6 *);
2.
1 *)
*) “ ”
21

33. Jane Liu 2010
2010
•
148 138 51 337
277 257 90 257
• 0-5.1%( 4.2%
4.9%)
• 303/624
48.6%
• 33%
22

34. Jane Liu 2010
1.
2.
3.
2005
100
18 (8.1%) 79 (35.6%)
50
84 (42.3%) 31 (14.0%)
50 100
23

35. Jane Liu 2010
1.
Zyrtec 5
1 α 5.03%
Zyrtec 1.25%
Actemra 80mg
2 α 2.5%
Actemra 200mg
Actemra 400mg
Enbrel 10mg
3 α 3.8%
Enbrel 25mg
2.
Actonel 17.5mg
1 α 2.5%
Bent 17.5mg
Slonnon Hi 10mg/2mL
2 α 2.96%
Novastan Hi 10mg/2mL
3 Gonatropin 5000 α 7.5%
24

36. Jane Liu 2010
3.
UFT E Granule T100
UFT E Granule T150
Tegafur
1 α 2.5
Uracil
UFT E Granule T200
UFT E Capsule T100
25

37. Jane Liu 2010
15
< >
NHI {
× ( 0.9 )
log x
log 2 + α* }
X( ) NHI
*( )
α
26

38. Jane Liu 2010
QOL (2006 )
Aricept 2006
-5.8%=-10.9%( ) 5.1% ( )
Aricept QOL( )
$10million $200million( ) 5.1%
27

39. Jane Liu 2010
2008
•Angiotension( Blopress 6 )
•SSRI ( Paxil 3 )
•Prograf ( )
•Remicade( )
✤ Blopress (
)
✤ Remicade QOL( )
28

40. Jane Liu 2010
2010
•ACTOS ( )
•Gilvec ( )
•Herceptin Intracenous Infusion ( )
•Tasigna( )
•Sprycel(
)
✤ ACTOS ( ):
✤ Gilvec ( ) 88%
✤ Herceptin Intracenous Infusion ( )
29

41. Jane Liu 2010
•
•
•
•
30

42. ✦ —
✦
✦
✦
✦
✦
✦
✦
31

43. ✦ “ ”
✦
✦
✦
✦ “ ”
✦
✦ /
✦ /
✦
✦
32

44. ICER
ΔCost ( D1 ( x ) + ND1 − D0 ( d0 ) + ND0 )
ICER = =
ΔE ΔE
ICER ⋅ ΔE = D1 ( x ) − D0 ( d0 ) − ND1 − ND0
D1 ( x ) = D0 ( d0 ) − ND1 + ND0 + ICER ⋅ ΔE
33

45. ICER
D1 ( x ) = D0 ( d0 ) − ND1 + ND0 + ICER ⋅ ΔE
x=D −1
1 ( x ) { D0 ( d0 ) + ( ND0 − ND1 ) + ICER ⋅ ΔE }
ND1 = ND0 ,
x=D −1
1 ( x ) { D0 ( d0 ) + ICER ⋅ ΔE }
D1 ( x ) = x D0 ( d0 ) = d0 ,
x = d0 + ICER ⋅ ΔE
34

46. ICER
ICER
x = d0 + ICER ⋅ ΔE
➡
ICER ⋅ ΔE
ICER
35

47. 1 3
2
3
4 3
5
6
7 IQWiG
36

48. 1
2
3
4 P4 P5
P3
P2
P1
37

49. IQWiG
(ICER )
(ICER )
6
4
3 5
1
2
CP0 CP6
38

50. ✦
✦
✦ICER
✦
✦ ICER NICE EF IQWiQ
✦
✦
39

51. © Jane 2010.12

52. Designer Perspectiv
e
Liu Jane
10 Times
Diligent
120%
Elegant
120%
iTemplate
Visionar
Treasure
y
2010.1 100%
2
© Jane 2010.12